Glutamine protects the small intestinal mucosa in anticancer drug-induced rat enteritis model.
Supportive therapy during chemotherapy has become essential, but effective preventive therapies to gastrointestinal mucosal injury are few. We investigated the efficacy of glutamine in rat anticancer drug-induced enteritis model. In this study, we used twenty male SD rats. They were divided into control, 5-fluorouracil (5-FU) (orally administered at 20 mg/kg day), 5-FU+glutamine (1000 mg/kg/day) and 5-FU+glutamine+fiber and oligosaccharide (GFO(®)) (1000 mg/kg/day) groups. All groups were sacrificed on day 6 and upper jejunums were excised. The jejunal villous height was measured in specimens. IgA level in jejunal washing solution, and serum diamine oxidase activity were also measured. The jejunal villous height was recognized as shorter in the specimen from 5-FU treated rats compared with 5-FU+glutamine treated rats (p<0.001). Serum diamine oxidase activity in 5-FU+glutamine group were significantly superior to that in 5-FU group (p=0.028). IgA level in jejunal washing solution tended to be higher in 5-FU+glutamine group than that in 5-FU group (p=0.076). On the other hand, serum diamine oxidase activity and IgA level in jejunal washing solution showed no significant difference between 5-FU+GFO and 5-FU treatment group. Our results suggest that glutamine showed protective effects on mucosal injury of small intestine in rat anticancer drug-induced enteritis model.
Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School.
Hirokazu
H
Takechi
Kazuaki
K
Mawatari
Nagakatsu
N
Harada
Yutaka
Y
Nakaya
Megumi
M
Asakura
Mutsumi
M
Aihara
Hiromitsu
H
Takizawa
Masakazu
M
Goto
Takeshi
T
Nishino
Takuya
T
Minato
Yoshihito
Y
Furukita
Yota
Y
Yamamoto
Yasuhiro
Y
Yuasa
Hiromichi
H
Yamai
Takahiro
T
Yoshida
Junichi
J
Seike
Akira
A
Tangoku
D000284:Administration, Oral; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D004043:Dietary Fiber / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D004751:Enteritis / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005973:Glutamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007070:Immunoglobulin A / Q000097:blood; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D007583:Jejunum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008297:Male; D009844:Oligosaccharides / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000970:Antineoplastic Agents; D004043:Dietary Fiber; D007070:Immunoglobulin A; D009844:Oligosaccharides; D005973:Glutamine; D006631:Amine Oxidase (Copper-Containing); D005472:Fluorouracil